Using metoclopramide to improve endoscopy for upper gastrointestinal bleeding
Premedication With Metoclopramide in Upper Gastrointestinal Bleeds a Prospective Double Blinded Single Center Randomized Control Trial in a Small Community Hospital
This study is testing if giving metoclopramide before endoscopy can help doctors see better and treat upper gastrointestinal bleeding more effectively for patients in the emergency room.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mercy Health System Research network |
| Locations | 1 site (Rockford, Illinois) |
| Trial ID | NCT05746377 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of metoclopramide in enhancing endoscopic interventions for patients experiencing upper gastrointestinal (GI) bleeding. The study will administer metoclopramide prior to endoscopy to determine if it reduces the need for repeat procedures and improves visibility of the GI walls. By stimulating stomach and intestinal activity, metoclopramide may facilitate better blood clearance, allowing physicians to more effectively identify and treat the source of bleeding. The trial will involve patients admitted to the emergency room or inpatient services with specific criteria related to upper GI bleeding.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are admitted with upper GI bleeding and are scheduled for an endoscopy within 24 hours.
Not a fit: Patients with known allergies to metoclopramide or those with certain neurological conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to fewer repeat endoscopies and improved treatment outcomes for patients with upper GI bleeding.
How similar studies have performed: While the use of metoclopramide in this context is being tested, similar studies have shown promise in enhancing endoscopic visibility and outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 and above * Admitted to ER or inpatient services at Javon Bea Hospital MercyHealth Riverside * Present with upper GI bleeding defined as fresh and bright red hematemesis, coffee-ground hematemesis or melena * Plan to undergo EGD within 24 hours since admission or since first symptoms * Calculated Glasgow-Blatchford score ≥ 2 Exclusion Criteria: * Failure to obtain informed consent * Known allergy to metoclopramide * Concurrent use of medications known to cause tardive dyskinesia (TD)/extrapyramidal symptoms/neuroleptic malignant syndrome * History of TD or dystonic reaction to metoclopramide * Pheochromocytoma, catecholamine-releasing paragangliomas * Parkinson's Disease * Epilepsy * Pregnancy or lactation * Previous gastrectomy
Where this trial is running
Rockford, Illinois
- Javon Bea Hospital-Riverside - MercyHealth — Rockford, Illinois, United States (Recruiting)
Study contacts
- Study coordinator: Mudassar K Sandozi, DO
- Email: msandozi@mhemail.org
- Phone: (815) 971-2544
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.